Sarepta Therapeutics, INC. (SRPT) — 10-Q Filings

10-Q Filings (6)

• Sarepta Swings to Q3 Loss Amid ELEVIDYS Safety Concerns — Nov 6, 2025 Risk: high
  Sarepta Therapeutics, Inc. reported a significant net loss of $179.9 million for the three months ended September 30, 2025, a stark contrast to the net income o
• Sarepta's ELEVIDYS Fuels Revenue Surge, Narrows Q2 Loss — Aug 6, 2025 Risk: medium
  Sarepta Therapeutics reported a significant increase in revenue for the three months ended June 30, 2025, reaching $345.2 million, up from $267.1 million in the
• Sarepta Therapeutics Files Q1 2025 10-Q — May 6, 2025 Risk: medium
  Sarepta Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and business operations, including info
• Sarepta Therapeutics Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
  Sarepta Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financ
• Sarepta Therapeutics Files Q2 2024 10-Q — Aug 7, 2024 Risk: medium
  Sarepta Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, incorporated in Delaware, operates in the pharmaceutical preparation
• Sarepta Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 1, 2024 Risk:
  Sarepta Therapeutics, Inc. (SRPT) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Sarepta Therapeutics, Inc. filed a 10-Q for the quarter ended Mar

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX